Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6759-6768
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Table 3 Completed studies with oral semaglutide and their main conclusions
Study | Ref. | Main conclusion |
PIONEER 1 | Aroda et al[57], 2019 | Oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo |
PIONEER 2 | Rodbard et al[58], 2019 | Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 wk in T2DM patients uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin |
PIONEER 3 | Rosenstock et al[59], 2019 | Oral semaglutide, 7 mg/d and 14 mg/d, compared with sitagliptin, resulted in significantly greater reductions in HbA1c over 26 wk |
PIONEER 4 | Pratley et al[60], 2019 | Oral semaglutide was non-inferior to subcutaneous liraglutide and superior to placebo in decreasing HbA1c, and superior in decreasing body weight compared with both liraglutide and placebo at week 26 |
PIONEER 5 | Mosenzon et al[61], 2019 | Oral semaglutide was effective in patients with type 2 diabetes and moderate renal impairment |
PIONEER 61 | Husain et al[62], 2019 | The cardiovascular risk profile of oral semaglutide was not inferior to that of placebo in high CV risk T2DM patients |
PIONEER 7 | Pieber et al[63], 2019 | Superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes |
PIONEER 7 EXTENSION | Buse et al[64], 2020 | Switching from sitagliptin to flexibly dosed oral semaglutide maintained HbA1c reductions, helped more patients achieve HbA1c targets with less use of additional glucose-lowering medication, and offers the potential for additional reductions in body weight |
PIONEER 8 | Zinman et al[65], 2019 | Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with T2DM |
PIONEER 9 | Yamada et al[66], 2020 | Oral semaglutide provides significant reductions in HbA1c compared with placebo in a dose-dependent manner in Japanese patients with T2DM |
PIONEER 10 | Yabe et al[67], 2020 | Once-daily oral semaglutide reduced HbA1c and bodyweight vs weekly dulaglutide 0.75 µg in Japanese T2DM patients |
- Citation: Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768
- URL: https://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i20.6759